Sanner Opens its First US Production Facility in North Carolina
Sanner, a provider of high-quality healthcare packaging and drug delivery solutions, officially opened its first US-based production facility in Greensboro, North Carolina. This marks a significant point in the company’s 134-year history, introducing localized production to better serve MedTech and pharmaceutical partners across North America.
“This is more than just a new facility,” said Christian Classen, CSO of Sanner Group. “It’s a bold step forward in our global journey, reinforcing our long-term commitment to supporting our customers in North America with local production, cutting-edge technology, and world-class service.”
Sanner’s investment in Greensboro expands its role as a supplier of primary packaging and as a Contract Development and Manufacturing Organization (CDMO) for the healthcare industry, combining global quality standards with local operations. Sanner provides manufacturing and contract development services for drug delivery devices, diagnostics, connected health devices, and pharmaceutical packaging.
The 60,500 sq. ft. site includes GMP-certified cleanrooms (ISO class 7 and 8), advanced injection molding, high-speed desiccant filling, and state-of-the-art laboratory facilities. The facility is designed for future growth, with 20,000 sq. ft. of expansion space included in the site.
“We’re grateful for the warm welcome and outstanding support from the Greensboro community,” added Classen. “This new site is a testament to what’s possible when global vision meets local partnership. Today, Sanner opens the door to a new chapter: this time, in the US”
With recent expansions in Germany, China, and now the United States, Sanner is well-positioned to support the evolving needs of global healthcare customers to bring innovative solutions closer to where they’re needed most.
most read
Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
VCI Welcomes US-EU Customs Deal
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Merck Acquires Chromatography Business from JSR Life Sciences
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
